Carcinogenesis Advance Access originally published online on January 9, 2009
Carcinogenesis 2009 30(3):538-543; doi:10.1093/carcin/bgp013
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance?
Laboratory for Health Protection Research, National Institute of Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands
* To whom correspondence should be addressed. Tel: +31 30 274 2102; Fax: +31 30 274 4446; Email: Harry.van.Steeg{at}rivm.nl
The DNA repair-deficient Xpa–/–p53+/– (Xpa/p53) mouse is a potent model for carcinogenicity testing, representing increased sensitivity toward genotoxic but surprisingly also toward true human non-genotoxic carcinogens. The mechanism of this increased sensitivity in Xpa/p53 mice toward non-genotoxic carcinogens is still unknown. Here, we investigated the mechanism of the human non-genotoxic carcinogen cyclosporine A (CsA) in the Xpa/p53 mouse model. Xpa/p53 mice exposed to CsA for 39 weeks showed a significantly increased lymphoma incidence as compared with untreated Xpa/p53 mice and CsA-treated wild-type (WT) mice. We excluded concealed genotoxicity of CsA in Xpa/p53 mice by mutant frequency analyses. As a next step, we used a genetic approach: immunodeficient DNA-PKcs mice, defective in the catalytic subunit of the DNA-dependent protein kinase, were crossed with Xpa and Xpa/p53 mice. Xpa/p53 mice had an increased lymphoma incidence with shorter latency times as compared with DNA-PKcs-deficient WT and Xpa mice. Surprisingly, also six of 15 DNA-PKcs/Xpa/p53 females had developed an adenocarcinoma of the mammary gland. Tumor responses in CsA-treated and DNA-PKcs-deficient Xpa/p53 mice were comparable as both genotypes developed mainly splenic lymphomas enriched in B lymphocytes. From our present studies, we hypothesize that levels of initiated precancerous cells are elevated in Xpa/p53 mice. These cells are insufficiently eliminated due to either suppression of the immune system by CsA or through immune-related DNA-PKcs deficiency. Based on the current studies and those conducted previously, we conclude that the Xpa/p53 model is an excellent adjunct to the current chronic rodent bioassay.
Abbreviations: CsA, cyclosporine A; FACS, fluorescence-activated cell sorting; MLN, mesenteric lymph node; DNA-PKcs, catalytic subunit of the DNA-dependent protein kinase; WT, wild-type
Received August 19, 2008; revised January 5, 2009; accepted January 5, 2009.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. J. Jonker, O. Bruning, M. van Iterson, M. M. Schaap, T. V. van der Hoeven, H. Vrieling, R. B. Beems, A. de Vries, H. van Steeg, T. M. Breit, et al. Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models Carcinogenesis, October 1, 2009; 30(10): 1805 - 1812. [Abstract] [Full Text] [PDF] |
||||
